(People’s Daily Health Client Reporter Wang Zhenya) “Solidly do a good job in the seventh batch of centralized procurement of medicines, centralized procurement of orthopedic spinal consumables and other key tasks.” On June 9, Chen Jinfu, member of the party group and deputy director of the National Medical Insurance Bureau The video conference on analyzing the situation of centralized pharmaceutical procurement emphasized the promotion of key tasks, which was regarded as a signal that the seventh centralized procurement had kicked off.

On June 13, Xie Yijiong, an industry insider, told a reporter from the People’s Daily Health Client that the seventh collection was slightly delayed. However, after the meeting of the National Medical Insurance Administration, related work will be put on the agenda. The seventh batch of centralized procurement includes 58 varieties, involving oncology drugs, Alzheimer’s disease drugs, flu magic drugs, etc., involving 234 companies, and the competition is still fierce.

Map of the National Medical Insurance Bureau.

Influenza magic drugs, antihypertensive drugs… Large varieties are the main focus of this round of centralized procurement

Since 2018, the reform of centralized procurement with volume has become normalized, In the new stage of institutionalization, so far, six batches of drugs have been purchased with volume, and a total of 234 kinds of drugs have been purchased. Together with the upcoming seventh batch of centralized procurement, nearly 300 varieties of drugs have been collected.

Xie Yijiong introduced, “The main direction of the seventh batch of centralized procurement is large varieties. It can be seen from the catalogue to be centralized procurement that large varieties of drugs such as oseltamivir, memantine, and nifedipine are included in this program. The difficulty and focus of this centralized procurement is to squeeze out the water of large varieties and reduce the price.”

Taking the magic flu drug oseltamivir as an example, the data from Minet.com shows that in China’s public In the terminal of medical institutions, the sales of oseltamivir rose to 2.5 billion yuan in 2018. In 2019, only the sales of oseltamivir of Dongyang Sunshine reached 4.273 billion yuan. For a long time, the market share of oseltamivir, the two companies of Roche and Dongyang Sunshine, has reached more than 80%.

And this time, oseltamivir has been reviewed by a total of 10 companies, and Li Cheng (pseudonym), the sales manager of one company, told the People’s Daily Health Client reporter that after the centralized procurement, the oseltamivir market was The pattern will change, and it is only possible to gain a place in this market by winning centralized procurement.

In Xie Yijiong’s view, there are many chemical companies entering the market this time, for example, there are as many as 27 companies competing for omeprazole sodium, and no one is willing to guarantee that every company can be selected. If you are squeezed out of the door, you will still bid fiercely in order to qualify for the election.

The collection of high-value orthopedic spine consumables is here

Spine surgery. Picture of Shenzhen Third People’s Hospital

In addition to the seventh centralized procurement, in the video conference on the analysis of the centralized medical procurement situation, Chen Jinfu, member of the party group and deputy director of the National Medical Insurance Bureau, emphasized the centralized procurement of orthopedic spinal consumables It is also the focus of this year’s work.

As early as February this year, at the State Council’s regular briefing on deepening the reform of centralized procurement of medicines and high-value medical consumables with volume, Chen Jinfu introduced that the varieties of centralized procurement really reflect the clinical needs, from In the past three years, there have been three types of high-value medical consumables. By the end of 2022, high-value medical consumables will cover 5 varieties.

From the perspective of the centralized procurement of high-value medical consumables, the average price of cardiac stents is reduced by 93%, and the average price of artificial hip joints and knee joints is reduced by 82%, which effectively squeezes the space for false heights. How much can the orthopaedic spinal consumables be reduced this time has become a topic of concern for patients and clinicians.

“Spine consumables are different from other orthopedic consumables. A small screw costs about 10,000 yuan, and most patients need more than 4. In this way, a spinal surgery often costs more than 100,000 yuan, and the main cost is It’s on the consumables.” Professor Dong Jian, director of the Department of Orthopedics, Zhongshan Hospital Affiliated to Fudan University, who has been engaged in orthopaedics for more than 30 years, told the People’s Daily Health Client reporter that because of the high cost, patients often encounter patients who should do three sections, but only do it. 1, which actually affects the patient’s treatment.

According to the “National Organization for the Centralized Procurement of Artificial Joint Medical Consumables (Draft for Comment)”, the centralized procurement of orthopaedic spine consumables covers 13 product systems and 8 types of materials. Dong Jian said that from the perspective of the scope of centralized collection, it basically covers the clinical needs. After centralized collection, it will be of great benefit to patients.

Actually, 2 rounds of centralized collection of spines have been carried out in Anhui Province before. In 2019, the average price of domestic products of Anhui orthopedic spine materials was reduced by 55.9%, and the maximum reduction of a single component was 95%. In July 2021, in the second round of centralized procurement in Anhui, the selected price will be reduced again on the basis of the first round. The highest drop has reached 82.88%, and the average drop has also reached 54.6%.